Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,524 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo.
Luke T, Wu H, Zhao J, Channappanavar R, Coleman CM, Jiao JA, Matsushita H, Liu Y, Postnikova EN, Ork BL, Glenn G, Flyer D, Defang G, Raviprakash K, Kochel T, Wang J, Nie W, Smith G, Hensley LE, Olinger GG, Kuhn JH, Holbrook MR, Johnson RF, Perlman S, Sullivan E, Frieman MB. Luke T, et al. Among authors: smith g. Sci Transl Med. 2016 Feb 17;8(326):326ra21. doi: 10.1126/scitranslmed.aaf1061. Sci Transl Med. 2016. PMID: 26888429
MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
Coleman CM, Venkataraman T, Liu YV, Glenn GM, Smith GE, Flyer DC, Frieman MB. Coleman CM, et al. Vaccine. 2017 Mar 14;35(12):1586-1589. doi: 10.1016/j.vaccine.2017.02.012. Epub 2017 Feb 23. Vaccine. 2017. PMID: 28237499 Free PMC article.
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE, Patel N, Lu H, Liu Y, Guebre-Xabier M, Piedra PA, Glenn G, Ellingsworth L, Smith G. Gilbert BE, et al. Among authors: smith g. Vaccine. 2018 Dec 18;36(52):8069-8078. doi: 10.1016/j.vaccine.2018.10.073. Epub 2018 Oct 30. Vaccine. 2018. PMID: 30389195
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate.
Bangaru S, Ozorowski G, Turner HL, Antanasijevic A, Huang D, Wang X, Torres JL, Diedrich JK, Tian JH, Portnoff AD, Patel N, Massare MJ, Yates JR 3rd, Nemazee D, Paulson JC, Glenn G, Smith G, Ward AB. Bangaru S, et al. Among authors: smith g. bioRxiv [Preprint]. 2020 Aug 6:2020.08.06.234674. doi: 10.1101/2020.08.06.234674. bioRxiv. 2020. Update in: Science. 2020 Nov 27;370(6520):1089-1094. doi: 10.1126/science.abe1502 PMID: 32793901 Free PMC article. Updated. Preprint.
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM. Keech C, et al. Among authors: smith g. N Engl J Med. 2020 Dec 10;383(24):2320-2332. doi: 10.1056/NEJMoa2026920. Epub 2020 Sep 2. N Engl J Med. 2020. PMID: 32877576 Free PMC article. Clinical Trial.
15,524 results
You have reached the last available page of results. Please see the User Guide for more information.